EA201690621A1 - Полиэтиленгликольсодержащие композиции - Google Patents

Полиэтиленгликольсодержащие композиции

Info

Publication number
EA201690621A1
EA201690621A1 EA201690621A EA201690621A EA201690621A1 EA 201690621 A1 EA201690621 A1 EA 201690621A1 EA 201690621 A EA201690621 A EA 201690621A EA 201690621 A EA201690621 A EA 201690621A EA 201690621 A1 EA201690621 A1 EA 201690621A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polyethylene glycol
containing compositions
salt
formula
pharmaceutical composition
Prior art date
Application number
EA201690621A
Other languages
English (en)
Inventor
Кендзи Мураи
Кадзухито Ямада
Original Assignee
Сантен Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сантен Фармасьютикал Ко., Лтд. filed Critical Сантен Фармасьютикал Ко., Лтд.
Publication of EA201690621A1 publication Critical patent/EA201690621A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)

Abstract

Изобретение относится к фармацевтической композиции, включающей соединение, представленное формулой (1), или его соль и полиэтиленгликоль.
EA201690621A 2013-09-20 2014-09-18 Полиэтиленгликольсодержащие композиции EA201690621A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013195329 2013-09-20
PCT/JP2014/074698 WO2015041294A1 (ja) 2013-09-20 2014-09-18 ポリエチレングリコール含有組成物

Publications (1)

Publication Number Publication Date
EA201690621A1 true EA201690621A1 (ru) 2016-07-29

Family

ID=52688941

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690621A EA201690621A1 (ru) 2013-09-20 2014-09-18 Полиэтиленгликольсодержащие композиции

Country Status (17)

Country Link
US (1) US20160228420A1 (ru)
EP (1) EP3047850A4 (ru)
JP (2) JP5856264B2 (ru)
KR (1) KR20160060656A (ru)
CN (1) CN105555271A (ru)
AU (1) AU2014322111A1 (ru)
BR (1) BR112016006153A2 (ru)
CA (1) CA2924628A1 (ru)
EA (1) EA201690621A1 (ru)
HK (2) HK1220632A1 (ru)
IL (1) IL244648A0 (ru)
MX (1) MX2016003566A (ru)
MY (1) MY163236A (ru)
PH (1) PH12016500461A1 (ru)
SG (1) SG11201602020QA (ru)
TW (1) TW201518291A (ru)
WO (1) WO2015041294A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9987368B2 (en) 2015-03-17 2018-06-05 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition comprising polypeptide
EP3272362B1 (en) 2015-03-18 2023-12-13 Santen Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
JP2017008047A (ja) * 2015-06-25 2017-01-12 参天製薬株式会社 注射剤
CA2991015A1 (en) * 2015-07-01 2017-01-05 Santen Pharmaceutical Co., Ltd. Depot preparation containing citric acid ester
CN106902117A (zh) * 2015-12-23 2017-06-30 瑞阳(苏州)生物科技有限公司 一种预防或治疗脉络膜新生血管形成的药物
JP7018939B2 (ja) * 2016-09-26 2022-02-14 ルヤン （スーチョウ） バイオロジー サイエンス アンド テクノロジー カンパニー，リミテッド 眼疾患の治療のための組成物ならびに使用および調製方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA833692B (en) * 1982-05-28 1985-02-27 Beecham Group Plc Pharmaceutical formulations
JPS59101478A (ja) * 1982-11-29 1984-06-12 Sunstar Inc リグスチライドを安定に配合した水系組成物
JPH09110698A (ja) * 1995-10-19 1997-04-28 Taiho Yakuhin Kogyo Kk 経口用医薬組成物の製造法
ES2368153T3 (es) * 2004-02-17 2011-11-14 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que presenta un grupo 4-piridilalquiltio que presenta amino (no) sustituido introducido en el mismo.
JP4626353B2 (ja) * 2004-02-17 2011-02-09 参天製薬株式会社 置換又は無置換アミノ基を導入した４−ピリジルアルキルチオ基を有する新規環式化合物
WO2005085201A1 (ja) * 2004-02-17 2005-09-15 Santen Pharmaceutical Co., Ltd. 置換又は無置換アミノ基を導入した４－ピリジルアルキルチオ基を有する新規環式化合物
US20060153920A1 (en) * 2004-09-24 2006-07-13 Ketan Amin Lyophilized pharmaceutical compositions
US8637070B2 (en) 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
WO2007076358A1 (en) 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
JP2010534201A (ja) 2007-07-20 2010-11-04 アルコン，インコーポレイテッド 受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の目への送達のための医薬製剤
ES2693696T3 (es) * 2007-11-26 2018-12-13 Merial, Inc. Sistemas de disolventes para formulaciones de unción dorsal continua para combatir parásitos
CN105362221A (zh) 2009-03-03 2016-03-02 爱尔康研究有限公司 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
JP5662719B2 (ja) * 2009-07-17 2015-02-04 参天製薬株式会社 ２−［［［２−［（ヒドロキシアセチル）アミノ］−４−ピリジニル］メチル］チオ］−ｎ−［４−（トリフルオロメトキシ）フェニル］−３−ピリジンカルボキサミドのベンゼンスルホン酸塩、その結晶、その結晶多形およびそれらの製造方法
EP3158991B1 (en) * 2010-01-28 2021-03-17 Eagle Pharmaceuticals, Inc. Formulations of bendamustine

Also Published As

Publication number Publication date
PH12016500461A1 (en) 2016-05-16
BR112016006153A2 (pt) 2017-08-01
MY163236A (en) 2017-08-30
JP5856264B2 (ja) 2016-02-09
IL244648A0 (en) 2016-04-21
CN105555271A (zh) 2016-05-04
TW201518291A (zh) 2015-05-16
WO2015041294A1 (ja) 2015-03-26
CA2924628A1 (en) 2015-03-26
JP2016094442A (ja) 2016-05-26
AU2014322111A1 (en) 2016-04-07
HK1221407A1 (zh) 2017-06-02
HK1220632A1 (zh) 2017-05-12
EP3047850A1 (en) 2016-07-27
US20160228420A1 (en) 2016-08-11
SG11201602020QA (en) 2016-04-28
EP3047850A4 (en) 2017-05-10
JP2015083565A (ja) 2015-04-30
MX2016003566A (es) 2016-06-02
KR20160060656A (ko) 2016-05-30

Similar Documents

Publication Publication Date Title
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
EA201490806A1 (ru) Комбинированный состав двух противовирусных соединений
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201590534A1 (ru) Новые бициклические производные
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
EA201590887A1 (ru) Композиция
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
MX2017014035A (es) Formas solidas novedosas.
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
RS54730B1 (sr) Inhibitori beta sekretaze
PH12016500461A1 (en) Polyethylene glycol-containing composition
CY1123194T1 (el) Νεες αντιβακτηριακες ενωσεις
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201692548A1 (ru) Минеральные аминокислотные комплексы активных веществ
EA201591451A1 (ru) Модуляторы flap
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
MX2018001517A (es) Derivados sustituidos de guanidina.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
EA201692270A1 (ru) Производные нафтиридиндиона